Vancouver, British Columbia–(Newsfile Corp. – February 16, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (OTC Pink: ENTBF) (FSE: 1XU1) (“ Entheon” or the “Company“), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce the appointment of Dr. Brian Jahns to the role of Chief Business Officer. Dr. Jahns brings more than 20 years of business…


Previous articlePT231 – Dr. Hassan Tetteh – Human Care Over Health Care
Next articleAlberta’s First Full-Service Psychedelic Therapy Clinic Opens in Calgary, Ushering in a New Era of Hope to Deal with the Growing Mental Health Crisis in Canada